Myriad Genetics launches Precise MRD test with select community oncologists

Myriad Genetics, Inc. -3.66%

Myriad Genetics, Inc.

MYGN

5.00

-3.66%

Myriad Genetics Inc. has commercially launched its Precise MRD molecular residual disease test with a select group of U.S. community oncology practices for breast cancer patients, marking an initial step toward broader commercialization later this year. The tumor-informed ctDNA assay uses whole-genome sequencing to create a personalized test and aims to enable ultrasensitive detection to support ongoing monitoring and treatment decisions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Myriad Genetics Inc. published the original content used to generate this news brief on March 02, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.